IRIS
MANZELLA, LIVIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.426
EU - Europa 1.816
AS - Asia 1.398
SA - Sud America 395
AF - Africa 268
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 2
Totale 7.307
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.310
IT - Italia 733
SG - Singapore 727
CN - Cina 389
IE - Irlanda 386
BR - Brasile 368
UA - Ucraina 249
CI - Costa d'Avorio 160
DE - Germania 131
IN - India 124
CA - Canada 106
RU - Federazione Russa 98
SN - Senegal 67
GB - Regno Unito 38
VN - Vietnam 35
FI - Finlandia 33
SE - Svezia 28
BE - Belgio 24
UZ - Uzbekistan 16
KR - Corea 15
NL - Olanda 15
FR - Francia 14
NG - Nigeria 14
CZ - Repubblica Ceca 13
TR - Turchia 13
AR - Argentina 12
BD - Bangladesh 11
HK - Hong Kong 10
PL - Polonia 10
IQ - Iraq 9
JP - Giappone 9
AT - Austria 8
IL - Israele 8
MA - Marocco 8
MX - Messico 8
CH - Svizzera 7
IR - Iran 7
GR - Grecia 6
ZA - Sudafrica 6
ES - Italia 5
LB - Libano 5
SA - Arabia Saudita 5
TN - Tunisia 5
EC - Ecuador 4
NO - Norvegia 4
AE - Emirati Arabi Uniti 3
CO - Colombia 3
RO - Romania 3
RS - Serbia 3
VE - Venezuela 3
AU - Australia 2
AZ - Azerbaigian 2
BG - Bulgaria 2
DZ - Algeria 2
EG - Egitto 2
JO - Giordania 2
KE - Kenya 2
LU - Lussemburgo 2
NI - Nicaragua 2
PE - Perù 2
PK - Pakistan 2
PY - Paraguay 2
AL - Albania 1
AM - Armenia 1
BH - Bahrain 1
EU - Europa 1
GA - Gabon 1
HU - Ungheria 1
KH - Cambogia 1
KZ - Kazakistan 1
LT - Lituania 1
LY - Libia 1
OM - Oman 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 7.307
Salva come PNG Salva come JPEG
Città #
Santa Clara 756
Singapore 467
Chandler 459
Dublin 386
Chicago 292
Jacksonville 257
Catania 176
Abidjan 160
Boardman 145
Nanjing 107
Cambridge 106
Lawrence 106
Andover 101
Ashburn 89
Kochi 89
Toronto 76
Grafing 69
Dakar 67
Civitanova Marche 58
Wilmington 52
San Mateo 50
Des Moines 49
Palermo 37
Los Angeles 35
New York 31
Munich 28
Nanchang 28
Beijing 27
Brussels 24
Hefei 24
Portland 24
São Paulo 24
The Dalles 24
Bari 23
Seattle 23
Columbus 22
Saint Petersburg 22
Shenyang 22
Dong Ket 21
Milan 19
Rome 19
Turku 19
Changsha 18
Hebei 18
Ottawa 18
Council Bluffs 17
Santa Venerina 17
Jiaxing 15
Tianjin 15
Abuja 14
Belo Horizonte 14
Bremen 14
Seoul 14
Aci Catena 13
Brno 13
Hanoi 12
Messina 12
Pune 12
Falls Church 10
Augusta 9
Brasília 9
Helsinki 9
Moscow 9
Rio de Janeiro 9
Curitiba 8
Leawood 8
Redmond 8
Tokyo 8
Cosenza 7
Hong Kong 7
Jinan 7
Mascalucia 7
Modica 7
Montreal 7
Norwalk 7
Porto Alegre 7
San Francisco 7
San Giovanni la Punta 7
Zhengzhou 7
Frankfurt am Main 6
Manaus 6
Ningbo 6
Phoenix 6
Tashkent 6
Washington 6
Agrigento 5
Edinburgh 5
Fairfield 5
Giardini-Naxos 5
Guarulhos 5
Hanover 5
Houston 5
Lappeenranta 5
Redwood City 5
Acireale 4
Antea 4
Ardabil 4
Bronte 4
Comiso 4
Delianuova 4
Totale 5.118
Salva come PNG Salva come JPEG
Nome #
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib 155
Activation of the s100a7/rage pathway by igf-1 contributes to angiogenesis in breast cancer 118
A Custom DNA-Based NGS Panel for the Molecular Characterization of Patients With Diffuse Gliomas: Diagnostic and Therapeutic Applications 117
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia 115
Mutational Analysis of BRCA1 and BRCA2 Genes in Breast Cancer Patients from Eastern Sicily 109
Activation of the IGF axis in thyroid cancer: Implications for tumorigenesis and treatment 104
Biomarkers and prognostic factors for malignant pleural mesothelioma 100
High BCR-ABL/GUSISlevels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib 98
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 91
Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice 90
Effect of combined epigenetic treatments and ectopic NIS expression on undifferentiated thyroid cancer cells 89
ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives 89
BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein 88
B-ALL relapses after autologous stem cell transplantation associated with a shift from e1a2 to e14a2 BCR-ABL transcripts: A case report 88
BCR-ABL TYROSINE KINASE ACTIVITY MODULATES THE PHOSPHORYLATION, LOCALIZATION AND FUNCTION OF INTERFERON REGULATORY FACTOR 5 (IRF-5) IN CHRONIC MYELOID LEUKEMIA CELLS 87
A novel system for semiautomatic sample processing in chronic myeloid leukaemia: Increasing throughput without impacting on molecular monitoring at time of sars-cov-2 pandemic 87
Combined use of sonographic and elastosonographic parameters can improve the diagnostic accuracy in thyroid nodules at risk of malignancy at cytological examination 86
AKT Inhibitors: New Weapons in the Fight Against Breast Cancer? 86
Short-term adverse effects of anticancer drugs in patients with type 2 diabetes 86
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 86
New insights in thyroid cancer and p53 family proteins 85
Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells.Cancer Res 84
Colony-forming cell assay detecting the co-expression of JAK2 V617F and BCR-ABL1 in the same clone: A case report 84
Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report 84
BCR-ABL Tyrosine Kinase Activity Modulates the Phosphorylation, Localization and Function of Interferon Regulatory Factor 5 (irf-5) in Chronic Myeloid Leukemia (CML) Cells 83
BCR-Abl tyrosine kinase activity modulates the expression of Interferon Regulatory Factor-5 in CML cells 81
BCR-ABL tyrosine kinase activity modulates the phosphorylation and the localization of Interferon Regulatory Factor 5 (IRF-5)in Chronic Myeloid Leukemia cells 81
Efficacy of Nilotinib in a CML Patient Expressing the Three-way Complex Variant Translocation t(2;9;22) 80
Next generation sequencing in a cohort of patients with rare sarcoma histotypes: A single institution experience 80
Pyrrolidinedithiocarbamate induces apoptosis in human acute myelogenous leukemic cells affecting NF-kappaB activity 79
Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts 79
Computational and Experimental Characterization of Two Nuclear Localization Signals and a Nuclear Export Signal that modulate BCR intracellular localization 78
BCR-ABL TYROSINE KINASE ACTIVITY MODULATES THE PHOSPHORYLATION, LOCALIZATION AND BIOLOGICAL FUNCTION OF INTERFERON REGULATORY FACTOR 5 IN CHRONIC MYELOID LEUKEMIA CELLS 78
BCR-ABL tyrosine kinase activity modulates survivin expression via PI3K/AKT 77
Optimal Response in a Patient With CML Expressing BCR-ABL1 E6A2 Fusion Transcript With Nilotinib Therapy: A Case Report 77
Suppression of survivin induced by BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs 76
Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients. 76
Additional Genetic Alterations and Clonal Evolution of MPNs with Double Mutations on the MPL Gene: Two Case Reports 75
c-IAP1, Survivin and Smac contribute to chemotherapy resistance in undifferentiated thyroid cancer cells 75
Mechanistic Translation of Melanoma Genetic Landscape in Enriched Pathways and Oncogenic Protein-Protein Interactions 75
Successful management of a pregnant patient with chronic myeloid leukemia receiving standard dose imatinib 74
Combined inhibition of bcl2 and bcr-abl1 exercises anti-leukemia activity but does not eradicate the primitive leukemic cells 74
IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation. 72
BCR-ABL tyrosine kinase activity modulates Survivin expression in CML cells 71
Detection and clinical implications of a novel BCR-ABL1 E12A2 insertion/deletion in a CML patient expressing the E13A2 isoform 70
SELECTIVE INHIHBITION OF LEUKEMIA CELL PROLIFERATION BY BCR-ABL ANTISENSE OLIGODEOXYNUCLEOTIDES SCIENCE 69
Opportunities and challenges of liquid biopsy in thyroid cancer 69
Potential Therapeutic Targets for Luminal Androgen Receptor Breast Cancer: What We Know so Far 68
The PU.1 transcription factor induces cyclin D2 expression in U937 cells 68
UNA INSERZIONE NEL DOMINIO TIROSIN-CHINASICO DI BCR-ABL POTREBBE CONTRIBUIRE ALLA RESISTENZA AD IMATINIB MESILATO DI PAZIENTI AFFETTI DA LEUCEMIA MIELOIDE CRONICA 68
Prognostic and Therapeutic Roles of the Insulin Growth Factor System in Glioblastoma 68
Silencing of survivin induced by BCR-ABL/JAK2/STAT3 pathway kills CML cells and sensitizes IM-resistant clones to hydroxyurea 66
Apoptosi mediata da Fas in cellule monocitiche umane 63
Targeting BCL-2 as a therapeutic strategy for primary p210BCR-ABL1-positive B-ALL cells 63
Espressione e funzione di OMI/HTRA2 in tumori solidi ed ematologici 62
POSSIBLE ROLE OF THE TRANSCRIPTION FACTOR INTERFERON REGULATORY FACTOR 1 (IRF-1) IN THE REGULATION OF ORNITHINE DECARBOXYLASE (ODC) GENE EXPRESSION DURING IFN GAMMA MACROPHAGE ACTIVATION 62
Rapid decline of philadelphia-positive metaphases after nilotinib treatment in a CML patient expressing a rare e14a3 BCR-ABL1 fusion transcript: A case report 62
Microenvironmental Determinants of Breast Cancer Metastasis: Focus on the Crucial Interplay Between Estrogen and Insulin/Insulin-Like Growth Factor Signaling 62
Ruolo del transcription factor interferon regulatory factor 1 (IRF-1) nella regolazione dell’espressione del gene della ornitina decarbossilasi durante l’attivazione di macrofagi umani mediata da IFN-gamma 61
Molecular pathogenesis and treatment perspectives for hypereosinophilia and hypereosinophilic syndromes 61
Ruolo delle IAPs e di Smac/DIABLO nella resistenza ai farmaci antiblastici di cellule di carcinoma indifferenziato della tiroide 60
High BCR-ABL/GUS(IS) Levels at Diagnosis Are Associated with Unfavorable Responses to Standard Dose Imatinib 59
Roles of Interferon Regulatory Factors in Chronic Myeloid Leukemia 58
ROLE OF INTERFERON REGULATORY FACTOR-1 (IRF-1) IN MONOCYTE FAS EXPRESSION AND FAS-MEDIATED APOPTOSIS 58
Modelling of the ABL and ARG proteins predicts two functionally critical regions that are natively unfolded 58
Molecular Analysis of Luminal Androgen Receptor Reveals Activated Pathways and Potential Therapeutic Targets in Breast Cancer 57
Diagnosis of Chronic Myeloid Leukemia Early in Pregnancy 57
POSITIVE AUTOREGULATION OF C-MYB BINDING SITES IN THE 5’ FLANKING REGION OF THE HUMAN C-MYB GENE 56
High BCR-ABL expression levels at diagnosis may predict unfavorable CML responses to Imatinib therapy 55
Delayed use of eribulin in a heavily pretreated liposarcoma patient, previously misdiagnosed as leiomyosarcoma 55
Implications of antidepressants use in breast cancer: A brief review 55
Possible role of the transcription factor interferon regulatory factor 1 (IRF-1) in the regulation of ornithine decarboxylase (ODC) gene expression during IFN gamma macrophage activation 54
Multiple primary malignances managed with surgical excision: a case report with next generation sequencing analysis 54
Hyperdiploidy associated with a high BCR-ABL transcript level may identify patients at risk of progression in chronic myeloid leukemia 53
ROLE OF INTERFERON REGULATORY FACTOR 1 IN MONOCYTE/MACROPHAGE DIFFERENTIATION 52
Experimental and Computational Characterization of Amino Acidic Residues in the BCR-ABL kinase domain contributing to TKI resistance in patients with Chronic Myeloid Leukemia 52
Role of NFkB in cytokine expression in normal Bone Marrow Cells 51
L’attività tirosin-chinasica di BCR/Abl modula l’espressione di IRF-5 51
HIGH BCR-ABL LEVELS AT DIAGNOSIS ARE ASSOCIATED WITH UNFAVORABLE RESPONS- ES TO IMATINIB 51
Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides 51
Transcriptional control of apoptosis related genes in Acute Myeloid Leukemia (AML) cells 50
High BCR-ABLIS expression at diagnosis and after 3 and 6 months of treatment are associated with unfavourable responses to Imatinib 50
Computational and biological characterization of nuclear import/export signals of the human BCR protein 50
Computational and experimental characterization of critical amino acidic residues in the BCR-ABL kinase domain explaining TKIs resistance in patients with chronic myeloid leukemia 49
The Insulin/IGF System in Colorectal Cancer Development and Resistance to Therapy 49
High BCR::ABL1 Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Proliferative Potential and Self-Renewal Ability 47
QUANTITATIVE ANALYSIS OF APOPTOTIS RELATED GENES IN CHRONIC MYELOGENOUS LEUKEMIA (CML) CELLS 47
IRF5 promotes the proliferation of human thyroid cancer cells. 46
The other side of the coin: dissecting molecular mechanisms behind hereditary breast cancer in search of therapeutic opportunities 46
The catalytic activity of BCR-ABL modulates survivin expression in chronic myelogenous leukemia cell lines 45
Long-acting insulin analogs and cancer 45
Role of Interferon Regulatory Factor-5 in Chronic Myeloid Leucemia 44
Ruolo dell’Interferon Regulatory Factor 5 (IRF-5) nel Carcinoma Tiroideo 44
PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance 44
RUOLO DEL FATTORE DI TRASRIZIONE IRF-1 NELLA REGOLAZIONE DEL GENE DELL’ODC DURANTE IL PROCESSO DI ATTIVAZIONE MACROFAGICA IFN-GAMMA DIPENDENTE 43
Role of Interferon Regulatory Factor-5 (IRF-5) in solid and haematological malignancies 43
Ruolo funzionale dell’Interferon Regulatory Factor 1 (IRF-1) nell’attivazione di macrofagi umani mediata dal IFN 43
Overexpression of inhibitors of apoptosis proteins and downregulation of smac/DIABLO in undifferentiated thyroid cancer cells resistant to chemotherapy 42
Role of the transcription factor Interferon Regulatory Factor 1 (IRF-1) in the expression of ornithine decarboxilase (ODC) gene during human macrophage IFN-gamma activation 41
High BCR-ABL/GUSIS Levels At Diagnosis Are Associated With Unfavorable Responses To Imatinib 41
Totale 6.895
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.240
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.240
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021625 19 42 62 12 142 18 55 4 129 14 91 37
2021/2022778 72 115 18 12 128 7 117 26 64 10 34 175
2022/20231.497 120 101 53 182 94 234 19 263 327 21 52 31
2023/2024791 65 106 36 36 34 190 7 59 5 27 157 69
2024/20252.977 47 456 127 147 609 390 178 83 191 244 309 196
2025/2026171 171 0 0 0 0 0 0 0 0 0 0 0
Totale 7.527